Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients

By Daniels LB, Sitapati AM, Zhang J, et al
Published September 15, 2020

Key Takeaways

Given that the use of statins, ACE inhibitors (ACEi) and angiotensin II is highly prevalent among individuals at risk for severe COVID-19, researchers sought to ascertain if and how the use of statin/ACEi/ARB in the month before hospital admission is associated with risk of severe outcome, and with time to severe outcome or disease recovery, among patients hospitalized for COVID-19. In this retrospective single-center study, they assessed 170 patients hospitalized for COVID-19 and 5,281 COVID-negative controls. Among COVID-positive inpatients, 53% developed severe disease. Those without severe disease showed a reduction in the risk of severe COVID-19 and had faster time to recovery in correlation with statin use prior to admission. In the COVID-negative cohort, the correlation between statin use and severe disease was smaller. Potential evidence was gained supporting faster time to recovery with ARB use. Findings thereby suggest correlation of statin use during the 30 days prior to admission for COVID-19 with a lower risk of developing severe COVID-19, and a faster time to recovery among patients without severe disease.

Read the full article on The American Journal of Cardiology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter